This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with interest the article by Bottorff and Hansten¹ on the long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors, which appeared in the August 2000 issue of the ARCHIVES. However, there are some inconsistencies that I would like to comment on.

1. In contrast to statements made by Bottorff and Hansten, cerivastatin, unlike other statins, has a dual metabolic pathway.² The major pathway seems to be via CYP2C8, with a significant contribution by CYP3A4. Clinically, this leads to such a low interaction profile with CYP3A4 inhibitors that cerivastatin does not require or necessitate dose reductions when used along with inhibitors of CYP3A4.^2-3 The number of clinical important interactors at CYP2C8 is small compared with those at CYP3A4.

2. Cyclosporine increases the area under the curve of pravastatin 5-fold.⁴ It is therefore misleading to state that pravastatin "because of the lack of clinically significant drug interactions can be . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?